BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 12701050)

  • 1. Low-dose oral glyburide reduces glucose production rates in patients with impaired fasting glucose.
    Bavirti S; Tayek JA
    Metabolism; 2003 Apr; 52(4):407-12. PubMed ID: 12701050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral sulfonylurea agents suppress hepatic glucose production in non-insulin-dependent diabetic individuals.
    DeFronzo RA; Simonson DC
    Diabetes Care; 1984; 7 Suppl 1():72-80. PubMed ID: 6428844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
    Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS
    Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetes and impaired glucose tolerance prevalences in Turkish patients with impaired fasting glucose.
    Tutuncuoğlu P; Saraç F; Saygili F; Ozgen AG; Yilmaz C; Tüzün M
    Acta Diabetol; 2008 Sep; 45(3):151-6. PubMed ID: 18496644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans.
    Meyer C; Pimenta W; Woerle HJ; Van Haeften T; Szoke E; Mitrakou A; Gerich J
    Diabetes Care; 2006 Aug; 29(8):1909-14. PubMed ID: 16873801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of hepatic and extrahepatic insulin resistance to the pathogenesis of impaired fasting glucose: role of increased rates of gluconeogenesis.
    Bock G; Chittilapilly E; Basu R; Toffolo G; Cobelli C; Chandramouli V; Landau BR; Rizza RA
    Diabetes; 2007 Jun; 56(6):1703-11. PubMed ID: 17384334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic characteristics and insulin resistance of impaired fasting glucose among the middle-aged and elderly Taiwanese.
    Chen LK; Lin MH; Chen ZJ; Hwang SJ; Tsai ST; Chiou ST
    Diabetes Res Clin Pract; 2006 Feb; 71(2):170-6. PubMed ID: 16026886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum high-molecular weight adiponectin decreases abruptly after an oral glucose load in subjects with normal glucose tolerance or impaired fasting glucose, but not those with impaired glucose tolerance or diabetes mellitus.
    Ozeki N; Hara K; Yatsuka C; Nakano T; Matsumoto S; Suetsugu M; Nakamachi T; Takebayashi K; Inukai T; Haruki K; Aso Y
    Metabolism; 2009 Oct; 58(10):1470-6. PubMed ID: 19592051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of glimepiride and glyburide on glucose counterregulation and recovery from hypoglycemia.
    Szoke E; Gosmanov NR; Sinkin JC; Nihalani A; Fender AB; Cryer PE; Meyer C; Gerich JE
    Metabolism; 2006 Jan; 55(1):78-83. PubMed ID: 16324923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the new American Diabetes Association definition for impaired fasting glucose improve its ability to predict type 2 diabetes mellitus in Spanish persons? The Asturias Study.
    Valdés S; Botas P; Delgado E; Alvarez F; Cadórniga FD
    Metabolism; 2008 Mar; 57(3):399-403. PubMed ID: 18249214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Characteristics of glycemic excursion in different subtypes of impaired glucose intolerance].
    Kang Y; Lu JM; Sun JF; Li CL; Wang XL; Zhang XQ; Lü ZH; Dou JT; Mu YM
    Zhonghua Yi Xue Za Zhi; 2009 Mar; 89(10):669-72. PubMed ID: 19595059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired fasting glucose is associated with increased arterial stiffness in elderly people without diabetes mellitus: the Rotterdam Study.
    van Popele NM; Elizabeth Hak A; Mattace-Raso FU; Bots ML; van der Kuip DA; Reneman RS; Hoeks AP; Hofman A; Grobbee DE; Witteman JC
    J Am Geriatr Soc; 2006 Mar; 54(3):397-404. PubMed ID: 16551305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of sulfonylurea treatment upon the mechanisms responsible for the insulin resistance in type II diabetes.
    Kolterman OG; Olefsky JM
    Diabetes Care; 1984; 7 Suppl 1():81-8. PubMed ID: 6376033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study.
    Arcavi L; Behar S; Caspi A; Reshef N; Boyko V; Knobler H
    Am Heart J; 2004 Feb; 147(2):239-45. PubMed ID: 14760320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fasting cut-offs in determining the prevalence of diabetes and intermediate glucose abnormality in a non-obese population.
    Sayeed MA; Mahtab H; Khanam PA; Keramat Ali SM; Chowdhury RI; Vaaler S; Hussain A; Azad Khan AK
    Bangladesh Med Res Counc Bull; 2004 Dec; 30(3):105-14. PubMed ID: 16240981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of impaired fasting glycemia, impaired glucose tolerance, and type 2 diabetes in hemodialyzed patients when applying new diagnostic criteria.
    Elbert A; Schreier L; Galli C; Beresan H; Lopez G; Traversa M; Berg G
    J Ren Nutr; 2006 Oct; 16(4):300-3. PubMed ID: 17046613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High prevalence of neuropathy in patients with impaired 60-minute oral glucose tolerance test but normal fasting and 120-minute glucose levels.
    Sahin M; Karatas M; Sahin M; Ertugrul D; Kulaksizoğlu M; Dogruk A; Gokcel A; Tutuncu NB; Guvener ND; Kutlu M
    Minerva Endocrinol; 2008 Dec; 33(4):289-96. PubMed ID: 18923366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type 2 diabetic patients may have a mild form of an injury response: a clinical research center study.
    Richardson AP; Tayek JA
    Am J Physiol Endocrinol Metab; 2002 Jun; 282(6):E1286-90. PubMed ID: 12006358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin and glyburide therapy: dosage, severity level of gestational diabetes, and pregnancy outcome.
    Langer O; Yogev Y; Xenakis EM; Rosenn B
    Am J Obstet Gynecol; 2005 Jan; 192(1):134-9. PubMed ID: 15672015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.